Results 171 to 180 of about 12,086 (222)

Thrombolytics: prospects for new agents

Expert Opinion on Pharmacotherapy, 2003
Thrombolytic therapy revolutionised the management of acute myocardial infarction (AMI). The ability to re-establish coronary artery patency with intravenous thrombolytic drugs has transformed our therapeutic approach, despite patency failures and re-occlusions.
Daniel B, McKenzie, Robert G, Wilcox
openaire   +2 more sources

Therapeutic use of thrombolytic agents

American Journal of Health-System Pharmacy, 1981
The use of thrombolytic agents for clotting disorders as compared with standard anticoagulant therapy is reviewed. The resolution rates of pulmonary emboli (PE) were examined in a comparison of streptokinase, urokinase, and heparin therapy in several studies.
R L, Stambaugh, M R, Alexander
openaire   +2 more sources

ANTITHROMBOTIC, ANTICOAGULANT, AND THROMBOLYTIC AGENTS

Dental Clinics of North America, 1996
There are a growing number of clinical indications for the use of antithrombotic, anticoagulant, and thrombolytic agents. Clinicians must recognize that these patients require multidisciplinary treatment and coordination of care, and an assessment of the patient's level of anticoagulation is imperative to ensure values that may preclude problematic ...
G T, Terezhalmy, A E, Lichtin
openaire   +2 more sources

Comparative safety of thrombolytic agents

The American Journal of Cardiology, 1991
Three available thrombolytic agents, streptokinase, alteplase, and anistreplase, have been shown to have similar effects on preservation of left ventricular function and mortality reduction after acute myocardial infarction (AMI). The agents are, however, quite different with respect to their safety profiles.
openaire   +2 more sources

Pharmacologic Review of Thrombolytic Agents

Critical Care Nursing Clinics of North America, 1990
Thrombolytic therapy has significantly reduced the morbidity and mortality that was once associated with acute myocardial infarction. Because of the substantial benefits associated with this therapy, investigation has intensified in search of the optimal agent or agents.
openaire   +2 more sources

New Strategies in the Development of Thrombolytic Agents

Blut, 1988
Recombinant DNA technology has allowed large-scale production of the physiological, fibrin-specific, plasminogen activators tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA). The results of clinical trials with these agents, mainly for the treatment of acute myocardial infarction, have revealed a ...
H R, Lijnen, D, Collen
openaire   +3 more sources

[Thrombolytic agents].

Nihon rinsho. Japanese journal of clinical medicine, 2014
Thrombolytic agents positively resolve existing thrombi by accelerating the activity of plasmin, a key enzyme of the fibrinolytic pathway. The main drug in use is a plasminogen activator (PA) which degrades plasminogen to plasmin. PA is classified into urokinase-type (u-PA) and tissue-type (t-PA).
openaire   +1 more source

Comparison of thrombolytic agents

Critical Care Nursing Quarterly, 1989
The new generation of plasminogen activators promises certain advantages over the first-generation agents, particularly enhanced clot specificity. The tissue distribution, half-life, therapeutic profile, and optimum dosage, however, need to be evaluated for each chemically different agent.
openaire   +2 more sources

Thrombolytic agents: A clinician's perspective

The American Journal of Medicine, 1987
Clinicians and researchers often have different perspectives: Clinicians deal with patients as individuals; researchers deal with them as members of groups whose characteristics can be defined statistically. Clinicians should be cautious and skeptical about new therapies, therefore, because the applicability of group-successful treatment to individual ...
openaire   +2 more sources

Thrombolytic agents

Annals of Emergency Medicine, 1989
H. Ostermann, U. Schmitz-Huebner
  +5 more sources